Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALTS Janone	$8.88 -0.9%	$5.57	$1.29 ▼ $9.84	$155M	2.14	226,863 shs	474,584 shs
ESPR Esperion Therapeutics	$0.83 +1.8%	$1.04	$0.69 ▼ $3.94	$165.44M	0.75	5.47 million shs	4.14 million shs
KPTI Karyopharm Therapeutics	$4.48 -1.5%	$5.10	$3.51 ▼ $17.40	$38.71M	0.33	82,066 shs	86,849 shs
SLN Silence Therapeutics	$5.19 +3.8%	$3.52	$1.97 ▼ $22.47	$155.34M	1.2	301,175 shs	112,578 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALTS Janone	-0.89%	+33.73%	+38.10%	+51.28%	+887,999,900.00%
ESPR Esperion Therapeutics	+1.81%	-2.15%	-8.00%	-49.72%	-60.25%
KPTI Karyopharm Therapeutics	-1.54%	-4.68%	-26.19%	-46.35%	-69.94%
SLN Silence Therapeutics	+3.80%	+0.97%	+48.29%	+9.96%	-76.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALTS Janone	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	4.0364 of 5 stars	3.3	3.0	0.0	3.9	3.2	1.7	0.6
KPTI Karyopharm Therapeutics	3.9731 of 5 stars	3.5	0.0	0.0	4.6	3.6	2.5	0.6
SLN Silence Therapeutics	3.7105 of 5 stars	4.4	4.0	0.0	0.0	3.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALTS Janone	0.00	N/A	N/A	N/A
ESPR Esperion Therapeutics	2.50	Moderate Buy	$6.25	648.77% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	864.29% Upside
SLN Silence Therapeutics	2.71	Moderate Buy	$33.83	551.89% Upside

Current Analyst Ratings Breakdown

Latest KPTI, ESPR, ALTS, and SLN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
5/9/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$4.00 ➝ $3.00
5/9/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $25.00
5/9/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $35.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALTS Janone	$18.05M	8.59	N/A	N/A	($0.67) per share	-13.25
ESPR Esperion Therapeutics	$259.57M	0.64	N/A	N/A	($3.85) per share	-0.22
KPTI Karyopharm Therapeutics	$142.13M	0.27	N/A	N/A	($1.47) per share	-3.05
SLN Silence Therapeutics	$27.70M	5.61	N/A	N/A	$0.71 per share	7.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALTS Janone	-$7.81M	N/A	0.00	∞	N/A	N/A	-2,940.01%	-39.81%	N/A
ESPR Esperion Therapeutics	-$209.25M	-$0.80	N/A	N/A	N/A	-29.37%	N/A	-10.77%	8/11/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$143.10M	-$13.26	N/A	N/A	N/A	-52.62%	N/A	-39.58%	8/5/2025 (Estimated)
SLN Silence Therapeutics	-$53.82M	-$1.50	N/A	N/A	N/A	-342.00%	-62.81%	-33.89%	N/A

Latest KPTI, ESPR, ALTS, and SLN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
5/8/2025	Q1 2025	SLN Silence Therapeutics	-$0.18	-$0.60	-$0.42	-$0.60	$3.58 million	$0.14 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALTS Janone	$1.22	13.74%	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALTS Janone	1.96	0.75	0.75
ESPR Esperion Therapeutics	N/A	1.85	1.37
KPTI Karyopharm Therapeutics	N/A	1.70	2.93
SLN Silence Therapeutics	N/A	9.31	9.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALTS Janone	6.27%
ESPR Esperion Therapeutics	47.39%
KPTI Karyopharm Therapeutics	66.44%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
ALTS Janone	4.90%
ESPR Esperion Therapeutics	1.70%
KPTI Karyopharm Therapeutics	2.75%
SLN Silence Therapeutics	2.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALTS Janone	170	17.46 million	13.38 million	N/A
ESPR Esperion Therapeutics	200	198.20 million	195.07 million	Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	122.72 million	Optionable
SLN Silence Therapeutics	100	29.93 million	N/A	Not Optionable

KPTI, ESPR, ALTS, and SLN Headlines

Recent News About These Companies

Silence Therapeutics plc (NASDAQ:SLN) Shares Bought by Woodline Partners LP

May 27 at 4:38 AM | marketbeat.com

Point72 Asset Management L.P. Has $4.36 Million Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

May 22, 2025 | marketbeat.com

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

May 21, 2025 | zacks.com

Silence Therapeutics plc (NASDAQ:SLN) Receives Average Recommendation of "Moderate Buy" from Analysts

May 15, 2025 | marketbeat.com

Integral Health Asset Management LLC Takes Position in Silence Therapeutics plc (NASDAQ:SLN)

May 14, 2025 | marketbeat.com

What is William Blair's Forecast for SLN FY2027 Earnings?

May 14, 2025 | marketbeat.com

Silence Therapeutics (NASDAQ:SLN) Price Target Lowered to $35.00 at Chardan Capital

May 11, 2025 | marketbeat.com

Silence Therapeutics (SLN) Projected to Post Quarterly Earnings on Thursday

May 10, 2025 | marketbeat.com

Silence Therapeutics plc GAAP EPS of -C$0.20

May 8, 2025 | seekingalpha.com

Cantor Fitzgerald L. P. Buys 205,534 Shares of Silence Therapeutics plc (NASDAQ:SLN)

May 7, 2025 | marketbeat.com

Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | finanznachrichten.de

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | businesswire.com

Silence Therapeutics plc (NASDAQ:SLN) Stock Holdings Increased by Nantahala Capital Management LLC

April 30, 2025 | marketbeat.com

Boothbay Fund Management LLC Has $2.42 Million Position in Silence Therapeutics plc (NASDAQ:SLN)

April 30, 2025 | marketbeat.com

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

April 23, 2025 | insidermonkey.com

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 5, 2025 | businesswire.com

Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

March 4, 2025 | zacks.com

Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

March 1, 2025 | uk.finance.yahoo.com

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

February 28, 2025 | seekingalpha.com

Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner

February 28, 2025 | biospace.com

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

February 27, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI, ESPR, ALTS, and SLN Company Descriptions

Janone NASDAQ:ALTS

$8.88 -0.08 (-0.89%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$8.86 -0.02 (-0.17%)

As of 05/28/2025 07:28 PM Eastern

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Esperion Therapeutics NASDAQ:ESPR

$0.83 +0.01 (+1.81%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$0.84 +0.01 (+0.87%)

As of 05/28/2025 07:57 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Karyopharm Therapeutics NASDAQ:KPTI

$4.48 -0.07 (-1.54%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$4.58 +0.10 (+2.23%)

As of 05/28/2025 07:56 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Silence Therapeutics NASDAQ:SLN

$5.19 +0.19 (+3.80%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$5.16 -0.04 (-0.67%)

As of 05/28/2025 07:34 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time